Person:
DEDE, FUAT

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

DEDE

First Name

FUAT

Name

Filters

2009 - 200912010 - 20152
Reset filters

Settings

Author: TUROĞLU, HALİL TURGUT × Has files: true ×

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of Association Between Fluoro-D-Glucose Positron Emission Tomography Uptake with Right Ventricular Functions in Patients with Chronic Thromboembolic Pulmonary Hypertension
    (ELSEVIER SCIENCE INC, 2013-10) YILDIZELİ, BEDRETTİN; Sunbul, Murat; Kivrak, Tarik; Oguz, Mustafa; Ozguven, Salih; Gungor, Serkan; Dede, Fuat; Turoglu, Halil Turgut; Yildizeli, Bedrettin; Mutlu, Bulent
  • Thumbnail Image
    PublicationOpen Access
    Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients
    (GALENOS YAYINCILIK, 2015-10-05) DEDE, FUAT; Aktas, Gul Ege; Turoglu, Halil Turgut; Erdil, Tanju Yusuf; Inanir, Sabahat; Dede, Fuat
    Objective: Geriatric patient population has special importance due to particular challenges. In addition to the increase in incidence of toxic nodular goiter (TNG) with age, it has a high incidence in the regions of low-medium iodine intake such as in our country. The aim of this study was to evaluate the overall outcome of high fixed dose radioiodine (RAI) therapy, and investigate the particular differences in the geriatric patient population. Methods: One hundred and three TNG patients treated with high dose I-131 (370-740 MBq) were retrospectively reviewed. The baseline characteristics; age, gender, scintigraphic patterns and thyroid function tests before and after treatment, as well as follow-up, duration of antithyroid drug (ATD) medication and achievement of euthyroid or hypothyroid state were evaluated. The patient population was divided into two groups as those=>65 years and those who were younger, in order to assess the effect of age. Results: Treatment success was 90% with single dose RAI therapy. Hyperthyroidism was treated in 7 +/- 7, 2 months after RAI administration. At the end of the first year, overall hypothyroidism rate was 30% and euthyroid state was achieved in 70% of patients. Age was found to be the only statistically significant variable effecting outcome. A higher ratio of euthyroidism was achieved in the geriatric patient population. Conclusion: High fixed dose I-131 treatment should be preferred in geriatric TNG patients in order to treat persistent hyperthyroidism rapidly. The result of this study suggests that high fixed dose RAI therapy is a successful modality in treatni g TNG, and high rates of euthyroidism can be achieved in geriatric patients.
  • Thumbnail Image
    PublicationOpen Access
    Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects
    (AMER PHYSIOLOGICAL SOC, 2009-03) HAKLAR, GONCAGÜL; Enc, Feruze Yilmaz; Oenes, Tunc; Akin, H. Levent; Dede, Fuat; Turoglu, H. Turgut; Uelfer, Goerzde; Bekiroglu, Nural; Haklar, Goncaguel; Rehfeld, Jens F.; Holst, Jens J.; Ulusoy, Nefise B.; Imeryuez, Nese
    Enc, FY, Ones,T, Akin HL, Dede F, Turoglu HT, Ulfer G, Bekiroglu N, Haklar G, Rehfeld JF, Holst JJ, Ulusoy NB, Imeryuz N. Orlistat accelerates gastric emptying and attenuates GIP release in healthy subjects. Am J Physiol Gastrointest Liver Physiol 296: G482-G489, 2009. First published December 24, 2008; doi:10.1152/ajpgi.90209.2008.-Orlistat, an inhibitor of digestive lipases, is widely used for the treatment of obesity. Previous reports on the effect of orally ingested orlistat together with a meal on gastric emptying and secretion of gut peptides that modulate postprandial responses are controversial. We investigated the effect of ingested orlistat on gastric emptying and plasma responses of gut peptides in response to a solid mixed meal with a moderate energy load. In healthy subjects, gastric emptying was determined using scintigraphy and studies were performed without and with 120 mg of orlistat in pellet form in random order. Orlistat shortened t lag and t half and decreased the area under the gastric emptying curve. Orlistat significantly attenuated the secretion of glucose-dependent insulinotropic polypeptide (GIP) but did not alter the plasma responses of cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1), pancreatic polypeptide (PP), and insulin. There was no peptide YY (PYY) response. Area under the curve of gastric emptying was positively correlated with integrated secretion of GIP (r = 0.786) in orlistat and was negatively correlated with integrated plasma response of GLP-1 (r = -0.75) in control experiments, implying that inhibition of fat absorption modifies determinants of gastric emptying of a meal. Orlistat administered similar to its use in obesity treatment accelerates gastric emptying of a solid mixed meal with a moderate energy load and profoundly attenuates release of GIP without appreciably altering plasma responses of CCK, GLP-1, and PP. Since GIP is being implemented in the development of obesity, its role in weight control attained by orlistat awaits further investigation.